Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Stock analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for Neurocrine Biosciences in a report released on Friday. Jefferies Group analyst B. Amin forecasts that the company will post earnings per share of ($0.26) for the quarter. Jefferies Group has a “Buy” rating and a $105.00 price target on the stock. Jefferies Group also issued estimates for Neurocrine Biosciences’ Q2 2018 earnings at $0.25 EPS, Q3 2018 earnings at ($0.13) EPS, Q4 2018 earnings at ($0.13) EPS and FY2022 earnings at $8.08 EPS.

NBIX has been the topic of several other research reports. Oppenheimer raised their price objective on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Citigroup reaffirmed a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $86.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Piper Jaffray Companies reaffirmed a “buy” rating and set a $76.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, October 25th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $84.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 5th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $81.13.

Shares of Neurocrine Biosciences (NBIX) traded up $1.73 on Monday, reaching $79.54. 1,025,800 shares of the company traded hands, compared to its average volume of 1,219,733. The company has a market capitalization of $7,040.00, a price-to-earnings ratio of -35.83 and a beta of 0.35. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences has a 52-week low of $38.43 and a 52-week high of $83.84.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period last year, the company earned ($0.43) earnings per share.

Several institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its stake in shares of Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares during the last quarter. Utah Retirement Systems grew its stake in shares of Neurocrine Biosciences by 1.9% in the second quarter. Utah Retirement Systems now owns 16,000 shares of the company’s stock worth $736,000 after acquiring an additional 300 shares during the last quarter. State Board of Administration of Florida Retirement System grew its stake in shares of Neurocrine Biosciences by 0.7% in the third quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after acquiring an additional 810 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Neurocrine Biosciences by 2.7% in the second quarter. American Century Companies Inc. now owns 33,705 shares of the company’s stock worth $1,550,000 after acquiring an additional 886 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 0.9% in the third quarter. Mutual of America Capital Management LLC now owns 112,862 shares of the company’s stock worth $6,916,000 after acquiring an additional 1,036 shares during the last quarter.

In other news, Director Gary A. Lyons sold 10,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $72.92, for a total value of $729,200.00. Following the transaction, the director now owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, December 28th. The shares were sold at an average price of $75.00, for a total transaction of $1,142,775.00. Following the completion of the transaction, the insider now directly owns 28,394 shares in the company, valued at approximately $2,129,550. The disclosure for this sale can be found here. In the last three months, insiders sold 116,405 shares of company stock worth $8,588,519. Insiders own 4.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Equities Analysts Set Expectations for Neurocrine Biosciences, Inc.’s Q1 2018 Earnings (NBIX)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/equities-analysts-set-expectations-for-neurocrine-biosciences-inc-s-q1-2018-earnings-nbix/1801263.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.